Petamig

PETAMIG – Petasites hybridus (L.) P. Gaertn., B. Mey. & Scherb 50.0 mg.

PETAMIG - Petasites hybridus (L.) P. Gaertn., B. Mey. & Scherb 50.0 mg. INDICATIONS: Indicated for the prophylactic treatment of migraines (migraine), reducing the frequency and intensity of episodes. CONTRAINDICATIONS: This medication is contraindicated for children under 6 years of age. This medicine should not be used by pregnant women without medical or dental surgeon advice. No animal studies (male or female) regarding reproductive toxicity have been performed. Therefore, pregnant or breastfeeding women should not use this product, as there are no studies that can guarantee safety in these situations. DRUG INTERACTIONS: There are no reports of drug interactions to date. WARNINGS: Patients who develop symptoms of unknown origin, such as fatigue, nausea, abdominal pain or dark urine, should interrupt treatment and undergo liver investigation tests. In case of hypersensitivity to the product, it is recommended to discontinue use and consult a doctor. DOSAGE: Adults: take 1 (one) capsule, orally, 2 (two) to 3 (three) times a day, as recommended by your doctor. Children over 6 years old: take 1 (one) capsule, orally, 1 (one) to 2 (two) times a day, according to medical advice. ADULT AND PEDIATRIC USE OVER 6 YEARS. ADVERSE REACTIONS: As with all medications, PETAMIG® can cause undesirable reactions, however these reactions do not occur in all patients and are described as mild to moderate. Very common adverse reactions: gastrointestinal disorders (nausea, mild diarrhea, abdominal pain, regurgitation, belching and bitter sensation in the mouth). Common adverse reactions: dermatological disorders (itching and rash). Uncommon adverse reactions: arthralgia (joint pain), dizziness and fatigue. MS: 1.1860.0103. SALE UNDER MEDICAL PRESCRIPTION.